Your shopping cart is currently empty

NSC23925 is a selective and effective inhibitor of P-glycoprotein (Pgp).


| Description | NSC23925 is a selective and effective inhibitor of P-glycoprotein (Pgp). |
| In vitro | NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. SKOV-3 cells with long-term exposure of 1 μM NSC23925 display stable growth in the culture medium. However, the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3TR or OVCAR8TR to cytotoxic drugs is 0.5 μM to 1 μM. The IC50 for NSC23925 is 8 μM in SKOV-3/SKOV-3TR and 25 μM in OVCAR8/OVCAR8TR cell lines. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 μM [1][2]. |
| In vivo | The usage of NSC23925 significantly prolongs the anticancer efficacy of paclitaxel in paclitaxel chemotherapy. Both saline alone and NSC23925 alone treated tumors grow progressively [1]. |
| Molecular Weight | 421.36 |
| Formula | C22H26Cl2N2O2 |
| Cas No. | 858474-14-3 |
| Smiles | Cl.Cl.COc1ccc(cc1)-c1cc(C(O)C2CCCCN2)c2ccccc2n1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.